- Home
- ACHV vs FLC Comparison
ACHV vs FLC Comparison
Compare ACHV & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACHV | FLC |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.0M | 184.0M |
| IPO Year | 2018 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ACHV | FLC |
|---|---|---|
| Price | $4.80 | $17.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | ★ 882.6K | 23.6K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.96 | $15.79 |
| 52 Week High | $6.03 | $18.09 |
Technical Indicators
Market Signals| Indicator | ACHV | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 71.66 | 55.86 |
| Support Level | $4.06 | $16.87 |
| Resistance Level | $5.30 | $17.24 |
| Average True Range (ATR) | 0.28 | 0.17 |
| MACD | 0.18 | 0.08 |
| Stochastic Oscillator | 83.08 | 91.54 |
Price Performance
Historical ComparisonAbout ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.